Approval · Notice of Compliance 12318 · 2011
VIRAMUNE: Notice of Compliance 12318
Issued May 6, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12318
- Date
- May 6, 2011
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosage form: 400 mg extended-release tablet
- Therapeutic class
- Antiretroviral agent / Non-nucleoside reverse transcriptase inhibitor with activity against Human Immunodeficiency Virus type 1 (HIV-1)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIRAMUNE | 02367289 | Cancelled Post Market |
Medicinal ingredients
- NEVIRAPINE 400 MG per TAB